156 related articles for article (PubMed ID: 22213031)
21. The c-erbB-2/neu proto-oncogene in human pituitary tumours.
Ezzat S; Zheng L; Smyth HS; Asa SL
Clin Endocrinol (Oxf); 1997 May; 46(5):599-606. PubMed ID: 9231056
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
[TBL] [Abstract][Full Text] [Related]
24. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
25. Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression.
Ostrowski J; Polkowski M; Paziewska A; Skrzypczak M; Goryca K; Rubel T; Kokoszyñska K; Rutkowski P; Nowecki ZI; Vel Dobosz AJ; Jarosz D; Ruka W; Wyrwicz LS
BMC Cancer; 2009 Nov; 9():413. PubMed ID: 19943934
[TBL] [Abstract][Full Text] [Related]
26. Protein expression and gene mutation status of KIT and PDGFRA in renal cell carcinoma.
Terada T
Histol Histopathol; 2012 Mar; 27(3):297-302. PubMed ID: 22237707
[TBL] [Abstract][Full Text] [Related]
27. C-kit expression and mutational analysis in medulloblastoma.
Chilton-Macneill S; Ho M; Hawkins C; Gassas A; Zielenska M; Baruchel S
Pediatr Dev Pathol; 2004; 7(5):493-8. PubMed ID: 15547773
[TBL] [Abstract][Full Text] [Related]
28. Kit gene in endometrial carcinoma: an immunohistochemical and mutational analysis.
Vandenput I; Debiec-Rychter M; Capoen A; Verbist G; Vergote I; Moerman P; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):203-5. PubMed ID: 21270602
[TBL] [Abstract][Full Text] [Related]
29. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
30. Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone.
Sulzbacher I; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2009; 41(7):630-3. PubMed ID: 20001342
[TBL] [Abstract][Full Text] [Related]
31. KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors.
Nishida H; Daa T; Kashima K; Arakane M; Urabe S; Yoshikawa Y; Gamachi A; Yokoyama S
Am J Dermatopathol; 2015 Dec; 37(12):898-905. PubMed ID: 25634571
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
33. Expression of genes FOLR1, BAG1 and LAPTM4B in functioning and non-functioning pituitary adenomas.
Larysz D; Zebracka-Gala J; Rudnik A; Hasse-Lazar K; Kowalska M; Jarząb M; Król A; Szpak-Ulczok S; Bażowski P; Jarząb B
Folia Neuropathol; 2012; 50(3):277-86. PubMed ID: 23023342
[TBL] [Abstract][Full Text] [Related]
34. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
[TBL] [Abstract][Full Text] [Related]
35. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
Kim DJ; Lee MH; Park TI; Bae HI
J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
[TBL] [Abstract][Full Text] [Related]
36. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
37. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.
Murakami A; Mori T; Sakai H; Murakami M; Yanai T; Hoshino Y; Maruo K
Vet Comp Oncol; 2011 Sep; 9(3):219-24. PubMed ID: 21848624
[TBL] [Abstract][Full Text] [Related]
38. Absence of activating mutations of CXCR4 in pituitary tumours.
Lee YH; Noh TW; Lee MK; Jameson JL; Lee EJ
Clin Endocrinol (Oxf); 2010 Feb; 72(2):209-13. PubMed ID: 19473177
[TBL] [Abstract][Full Text] [Related]
39. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
Sihto H; Franssila K; Tanner M; Vasama-Nolvi C; Sarlomo-Rikala M; Nupponen NN; Joensuu H; Isola J
Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193
[TBL] [Abstract][Full Text] [Related]
40. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort.
Battochio A; Mohammed S; Winthrop D; Lefresne S; Mulder K; Chu Q; O'Hara C; Lai R
Am J Clin Pathol; 2010 Jan; 133(1):149-55. PubMed ID: 20023271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
